Differences in blood microRNA and circulating tumor cells during immunotherapy
The Difference of microRNA Signature(S) and Circulating Tumor Cells in Blood Among Cancer Patients Before and Afte Immunotherapy
Chang Gung Memorial Hospital · NCT07260370
This project will test whether levels of microRNA and circulating tumor cells in the blood change before and after immunotherapy in adults with cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Taoyuan City) |
| Trial ID | NCT07260370 on ClinicalTrials.gov |
What this trial studies
This observational project will enroll 300 adults with physician-diagnosed cancer who are starting immunotherapy. Participants will give small blood samples (two 10 mL tubes, up to three times) before and after treatment and investigators may review existing pathology tissue when needed. The project will compare quantities of free microRNAs, counts of circulating tumor cells, and surface antigen expression on both blood cells and available tumor tissue. Statistical analyses will identify patterns that correlate with treatment status and antigen expression.
Who should consider this trial
Good fit: Adults aged 20 or older who have been diagnosed with cancer and are scheduled to receive immunotherapy and can give informed consent are ideal candidates.
Not a fit: Patients under age 20, those who decline participation, or those unable to provide the required blood samples are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the results could help clinicians use blood-based microRNA and circulating tumor cell measurements to monitor or predict response to immunotherapy.
How similar studies have performed: Previous research has shown that circulating tumor cells and microRNA can reflect cancer biology and sometimes predict therapy response, but findings have been mixed and these biomarkers are not yet standard clinical tools.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged above 20 years. 2. A patient diagnosed with cancer with immunotherapy 3. Competent to give informed consent and agree to join the study. Exclusion Criteria: 1. Aged \< 20 years. 2. Refuse to join the study
Where this trial is running
Taoyuan City
- Linkou Chang Gung Memorial Hospital — Taoyuan City, Taiwan (RECRUITING)
Study contacts
- Principal investigator: Chia-Hsun Hsieh, PhD — Division of Oncology, Chang Gung Memorial Hospital
- Study coordinator: Chia-Hsun Hsieh, PhD
- Email: wisdom5000@gmail.com
- Phone: 0975366137
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: microRNA, Circulating Tumor Cells, Immunotherapy, Cancer, Plasma, Circulating Tumor Cell